316 related articles for article (PubMed ID: 11606916)
1. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
3. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
4. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
Sami N; Bhol KC; Razzaque Ahmed A
Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
[TBL] [Abstract][Full Text] [Related]
6. The role of IVIg treatment in severe pemphigus vulgaris.
Baum S; Scope A; Barzilai A; Azizi E; Trau H
J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
8. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
Szép Z; Danilla T; Buchvald D
Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438
[TBL] [Abstract][Full Text] [Related]
10. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
Werth VP
Arch Dermatol; 1996 Dec; 132(12):1435-9. PubMed ID: 8961871
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
13. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
Bystryn JC; Jiao D
Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
[TBL] [Abstract][Full Text] [Related]
14. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
15. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.
Bhol KC; Desai A; Kumari S; Colon JE; Ahmed AR
Clin Immunol; 2001 Aug; 100(2):172-80. PubMed ID: 11465946
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
17. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
Mahajan VK; Sharma NL; Sharma RC; Garg G
Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
Sami N; Qureshi A; Ruocco E; Ahmed AR
Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
20. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
